-
National Preparedness Month promotes emergency preparedness and planning National News
-
White House pushing Congress to focus on reliability of US pharmaceutical supply chains. National News
-
Congress continues debating the best approach to address prescription drug reform National News
-
COA Warns Congress of Eroding Cancer Care Infrastructure and Misguided Legislative Proposals. Affiliate Association News/COA News
|
|
MOASC greatly appreciates the members who have renewed their support for 2021-2021.
May & June: Cancer and Blood Care Specialists; Cancer and Blood Specialty Clinic; Cancer Care Institute; Howard H. Cheng, MD & Associates, LLC; Coast Hematology Oncology Associates, Inc; Compassionate Oncology Care; Global Oncology Inc.; Daniel R. Lewis, MD; Raghu Nandan, MD, Inc.; Ranjan K. Sapra, MD; Carlos Say, MD; South County Hematology Oncology, Inc.
July & August: James Berenson, MD; California Cancer Associates for Research & Excellence (CCARE); City of Hope; Comprehensive Blood and Cancer Center; Hematology Oncology Consultants; William H. Isacoff, MD, Inc.; Wellness Oncology & Hematology.
September: Cancer Center Oncology Medical Group.
If you don’t see your name listed, please join today and join your colleagues in the many clinical and practice management programs presented throughout the year. You can’t afford not to join!
|
|
MOASC Programs - Save the Dates - All Times are Pacific
|
|
September 22, 5:30-6:30pm PDT, MOASC will host a live webinar on Prostate Cancer Awareness, with panel discussions on initial treatment of Metastatic Castration Sensitive Prostate Cancer/Increase in newly diagnosed; current thoughts on radiation for primary tumor in Metastatic Disease and new treatments in Castration Resistance Disease in conjunction with genomic testing/PARP inhibitors presented by: Ashkan Lashkari, M.D., MOASC President; Christopher DeSantis, California Urological Association; John Lam, M.D., Kaiser Permanente, Los Angeles; Nataliya Mar, M.D., Assistant Professor, UCI and Steven N. Seyedin, M.D., Assistant Clinical Professor, UCI. This event is complementary but registration is required.
|
|
September 25, 2021, Cedars Sinai’s 2021 Annual Seminar for GI Nurses and Associates directs content to GI Nurses and Interdisciplinary Professionals.
|
|
October 2, 2021, 8am-12pm SAVE THE DATE for MOASC’s Spotlight On Oncology. MOASC Board member, Jason Zell, MD will moderate discussions on: Melanoma presented by Omid Hamid, MD; Genitourinary Cancer presented by Nataliya Mar, MD; Upper Gastrointestinal Cancer presented by Jennifer Valerin, MD; Lower Gastrointestinal Cancer presented by May T. Cho, MD; Lung Cancer presented by Misako Nagasaka, MD, and Breast Cancer presented by Ritesh Parajuli, M.D.
|
|
October 29-30, the University of California San Diego invites you to their inaugural Delivering Discoveries: Updates in Oncology CME conference. The diagnosis and management of cancer patients is increasingly complex and requires multidisciplinary management. This 1.5 day event will address all aspects of cancer from basic science research, advances in clinical care, to community-based approaches that optimize prevention and interception.
|
|
November 4 and November 10, SAVE THE DATE for MOASC’S Annual Practice Management Series! The virtual Educational Series will be presented in two tracks.
Track one – Oncology Administration November 4 from 11:45am – 3:15pm
Topics include: How to deal with Employee Fatigue, Time Management and Process Automation for Practices.
Track two – Oncology Billing November 10 from 11:45am – 3:15pm
Topics include: 2022 Billing updates, Overview of Medicare Regulations, Positioning Your Physician Organization for Financial Success and How to Increase Revenue.
There will be opportunity for attendees to spend time Networking in the Zoom Room with our gracious Sponsors. Thank you, AstraZeneca, BeiGene, Bristol Myers Squibb, Grail, Inc., Oncopeptides, Pfizer Oncology, Takeda Oncology, AbbVie, Astellas, Daiichi Sakyo, Inc., Incyte, Johnson and Johnson, Merck, Novartis, ADC Therapeutics, Agios Pharmaceuticals, Exact Sciences, Foundation Medicine, Gilead, G1 Therapeutics, Guardant Health, Kite Pharma, Lilly Oncology, Morphosys, Inc., Myovant Sciences, Pharmacyclics, Sanofi-Genzyme, Seagen, Stemline Therapeutics, Walgreens Coherus Biosciences, Rigel Pharmaceuticals, VerdePharm Health.
Thank you for attending the September 8 virtual presentation on Enhancing Personalized Medicine in advanced Ovarian Cancer, presented by Bradley J. Monk, MD, FACS, FACOG from Arizona Oncology. If you missed this informative program, the recording, slides, evaluation link for CME credit and questions are here.
|
|
The California Department of Managed Health Care (DMHC) protects the health care rights of more than 27.7 million Californians and ensures a stable health care delivery system. The Department has helped more than 2.5 million Californians resolve health plan problems through the Help Center. Information and assistance is available at www.HealthHelp.ca.gov or by calling 1-888-466-2219. DMHC is seeking dynamic and solution-oriented health care professionals and advocates to serve on the DMHC Health Equity and Quality Committee. The Committee will provide initial recommendations to the DMHC Director for standard health equity and quality measures, including annual benchmark standards for assessing equity and quality in health care delivery. Individuals with training and experience in health care quality, quality improvement activities, health equity, social determinants of health, and/or health disparities are encouraged to apply. In order for the Committee composition to reflect the diversity of the State of California, the Department is seeking individuals who represent and have knowledge of diverse communities, including the racial, cultural, ethnic, sexual orientation, gender, economic, linguistic, age, disability, and geographical diversity of California. For more information, please read the Committee Member Solicitation and Committee Overview. Interested candidates must submit required documents by October 15, 2021.
September 23, 2021, CMA is hosting a webinar to provide physician practices the information they need to avoid billing challenges to two of the most pressing issues facing medical practices at this stage of the COVID-19 pandemic: Telehealth and COVID-19 vaccine administration. Speakers will provide a brief overview of the current federal and state telehealth flexibilities in place as a result of the COVID-19 pandemic.
|
|
Prostate Cancer: Talk to Your Patients about Screening
During Prostate Cancer Awareness Month, talk to your patients about the nature and risk of prostate cancer, and help them make an informed decision about screening. Medicare covers prostate cancer screenings.
|
|
September 22 – 23, Noridian invites you to experience their Virtual Fall Symposium. Meet and engage with your provider education Part A and B team members, where you may pick and choose which sessions you're interested in attending. Each session will be 55 minutes long and you will be required to sign up for each session provided.
|
|
September 23, Preventive Services: Flu and PPV Vaccines
This webinar will review the coverage, coding and billing guidelines under Medicare Part B for Influenza and Pneumococcal Pneumonia Virus vaccinations.
|
|
Quarterly Medicare Updates - A/B Webinar - October 5, 2021
This event includes: CMS and Noridian Updates, October 2021 Quarterly Provider Updates, Change Requests (CR), Recurring Updates, Special Editions (SE), and Resources
|
|
Quarterly Medicare Updates - A/B - After Hours Webinar - October 14, 2021
This event includes: CMS and Noridian Updates, October 2021 Quarterly Provider Updates, Change Requests (CR), Recurring Updates, Special Editions (SE), and Resources
|
|
MLN Connects - September 9, 2021
CMS has made available the latest edition of the MLN Connects.
|
|
October 5, 2021, 10am PDT, join Bobbi Buell for a free webinar on the Proposed Outpatient Prospective Payment System Rule which is slated to start January 1, 2022.
|
|
National Preparedness Month (NPM) is recognized each September to promote personal, family, and whole community emergency preparedness and planning throughout the year. Join CDC for a webinar on Wednesday, September 15, at 10am PST.
|
|
The Biden Administration is pushing Congress to focus on two priority objectives and six recommendations to address the reliability of US pharmaceutical supply chains. |
|
As Congress continues debating the best approach to address prescription drug reform, it is more critical than ever that patient voices are heard. Calls to repeal the non-interference (NI) provision in Medicare Part D are increasing, and it is vital that policymakers understand the negative impact this policy can have on the patients that you represent. Repealing NI would likely result in the implementation of a restrictive formulary for Medicare beneficiaries, ultimately limiting their access to the medications they need to treat chronic and acute conditions. This policy has the ability to undermine the comprehensive coverage that seniors and individuals with disabilities rely upon to maintain their health and could put effective health treatments at risk. Please sign on with the Chronic Care Policy Alliance and the 30 organizations that have already called upon Congress to protect prescription drug coverage in Medicare by opposing the repeal of NI. Please Sign On if you would like your organization added to the list of signers. Thank you very much for your leadership and advocacy on behalf of your patients.
|
|
As of Jan. 1, 2021, there are new Evaluation and Management (E/M) Services Guidelines for outpatient and ambulatory services that encompass specific areas of risk defined in the social determinants of health (SDOH). Walk through a coding example scenario that explains how properly capturing SDOH information serves patients and impacts reimbursement.
|
|
A Biden administration plan to lower prescription-drug prices offers the first detailed road map of administrative actions the White House would support in addition to legislation aimed at driving down costs. The plan, which was released last week, backs legislation from congressional Democrats, including a push to empower the federal government to negotiate for drug prices in Medicare and pass those lower costs along to the private sector.
|
|
Affiliate Association News |
|
UC Davis is conducting a Medical Oncologist Survey. If you are a medical oncologist, we'd like to invite you to participate in a survey about genetic counseling and for the chance to win an iPad. Please contact jachuynh@ucdavis.edu with any questions.
|
|
On October 4, 1-2pm PDT, ASH is hosting the final of their new series titled the ASH Advocacy Webinar Series, Working with Advocacy Groups and Coalitions: How to Amplify Your Voice in Washington. ASH is committed to educating its members on how to become effective advocates for hematology research and practice. Registration is free and open to all interested.
|
|
ASCO has created a temporary online job board to help connect oncology trainees with positions of employment, in lieu of the in-person networking received at the ASCO Annual Meeting. Between September 16 and October 15, 2021, trainees can view the list of available jobs, seek out more info, and apply. If you are recruiting trainees for open positions at your organization, please fill out the form or forward it to your hiring department.
|
|
COA News
COA Warns Congress of Eroding Cancer Care Infrastructure and Misguided Legislative Proposals. Last week, COA sent a letter to Congressional leaders warning of the impact that misguided legislative proposals under consideration in Washington could have on the nation’s eroding cancer care infrastructure.
|
|
MOASC acknowledges and thanks Guardant Health as an annual sponsor. Please welcome and THANK them for supporting your organization, when they call or e-mail you.
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics.
|
|
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma.
The accepted BLA, filed in collaboration with Novartis, is supported by the positive global Phase 3 RATIONALE 302 trial in patients with previously treated, advanced or metastatic ESCC and safety data from tislelizumab’s broad clinical program. With its second internally developed medicine filed outside China, BeiGene furthers its commitment to expanding access to innovative treatments for cancer patients worldwide.
|
|
Incyte Corp. strives to provide assistance to physicians and patient education through their patient webinar programs. Please share this invitation with your patients and their caregivers who have been diagnosed with myeloproliferative neoplasms (MPN), including Polycythemia Vera, Essential thrombocythemia and Myelofibrosis. They will hear from Incyte Oncology Clinical Nurse Educators about MPNs. The last two live webinars are September 21 & 22. Thank you.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
